Literature DB >> 23125278

Management of pericardial effusion.

Massimo Imazio1, Yehuda Adler.   

Abstract

Pericardial effusion is a common finding in clinical practice either as incidental finding or manifestation of a systemic or cardiac disease. The spectrum of pericardial effusions ranges from mild asymptomatic effusions to cardiac tamponade. The aetiology is varied (infectious, neoplastic, autoimmune, metabolic, and drug-related), being tuberculosis the leading cause of pericardial effusions in developing countries and all over the world, while concurrent HIV infection may have an important promoting role in this setting. Management is guided by the haemodynamic impact, size, presence of inflammation (i.e. pericarditis), associated medical conditions, and the aetiology whenever possible. Pericardiocentesis is mandatory for cardiac tamponade and when a bacterial or neoplastic aetiology is suspected. Pericardial biopsy is generally reserved for cases with recurrent cardiac tamponade or persistence without a defined aetiology, especially when a bacterial or neoplastic aetiology is suspected and cannot be assessed by other conventional and less invasive means. A true isolated effusion may not require a specific treatment if the patient is asymptomatic, but large ones are at risk of progression to cardiac tamponade (up to one third). Pericardiocentesis alone may be curative for large effusions, but recurrences are also common and pericardiectomy or less invasive options (i.e. pericardial window) should be considered with recurrent cardiac tamponade or symptomatic pericardial effusion (either circumferential or loculated). The aim of this paper was to summarize and critically evaluate current knowledge on the management of pericardial effusion.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23125278     DOI: 10.1093/eurheartj/ehs372

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  57 in total

1.  Pericardial Effusion in Patients with End-Stage Renal Disease.

Authors:  Kay-Won Chang; Gabriel Marcelo Aisenberg
Journal:  Tex Heart Inst J       Date:  2015-12-01

2.  Effusive-Constrictive Pericarditis After Pericardiocentesis: Incidence, Associated Findings, and Natural History.

Authors:  Kye Hun Kim; William R Miranda; Larry J Sinak; Faisal F Syed; Rowlens M Melduni; Raul E Espinosa; Garvan C Kane; Jae K Oh
Journal:  JACC Cardiovasc Imaging       Date:  2017-10-05

3.  Cytopathology of pericardial effusions : Experience from a tertiary center of cardiology.

Authors:  C Gecmen; G G Gecmen; D Ece; M Kahyaoğlu; A Kalayci; C Y Karabay; O Candan; M E Isik; F Yilmaz; O Akgun; M Celik; I A Izgi; C Kirma; S Keser
Journal:  Herz       Date:  2017-07-10       Impact factor: 1.443

Review 4.  Pericardial Effusion and Cardiac Tamponade in the New Millennium.

Authors:  Brian D Hoit
Journal:  Curr Cardiol Rep       Date:  2017-07       Impact factor: 2.931

Review 5.  Pericardial Disease Associated with Malignancy.

Authors:  Ryan Schusler; Shari L Meyerson
Journal:  Curr Cardiol Rep       Date:  2018-08-20       Impact factor: 2.931

6.  Enterobacter cloacae pericardial effusion in a frail elderly patient.

Authors:  H J Blundell; C A Mason
Journal:  BMJ Case Rep       Date:  2015-02-19

7.  Pericardial effusion requiring surgical intervention after stem cell transplantation: a case series.

Authors:  T M Pfeiffer; S J Rotz; T D Ryan; R Hirsch; M Taylor; R Chima; A Pate; J Hlavaty; M Grimley; K Myers; J El-Bietar; S M Davies; S Jodele; C Dandoy
Journal:  Bone Marrow Transplant       Date:  2016-12-19       Impact factor: 5.483

Review 8.  European Guidelines on Pericardial Diseases: a Focused Review of Novel Aspects.

Authors:  Alexander Fardman; Philippe Charron; Massimo Imazio; Yehuda Adler
Journal:  Curr Cardiol Rep       Date:  2016-05       Impact factor: 2.931

9.  Metropolitan W135 meningococcal compressive pericarditis treated with intrapericardial fibrinolysis.

Authors:  Aude Garin; Florent Bavozet
Journal:  BMJ Case Rep       Date:  2018-10-16

10.  Determinants of Survival After Emergency Intrapericardial Cisplatin Treatment in Cancer Patients with Recurrent Hemodynamic Instability After Pericardiocentesis.

Authors:  Szymon Darocha; Michał Wilk; Anna Walaszkowska-Czyż; Jarosław Kępski; Rafał Mańczak; Marcin Kurzyna; Adam Torbicki; Sebastian Szmit
Journal:  In Vivo       Date:  2018 Mar-Apr       Impact factor: 2.155

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.